Specialty Pharmacy

Fentanyl, heroin, hydrocodone, and methamphetamine among the most frequently mentioned drugs connected to overdoses, according to a new report from the CDC.

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer. 

Romiplostim (NPLATE, Amgen) approved for the treatment of pediatric patients with immune thrombocytopenia who have had an insufficient response to other therapies.

Updated data from the HAVEN 2 study showed that the majority of children treated with emiciziumab-kxwh (Hemlibra, Genentech) experienced sustained bleed control.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

A recent study found further evidence that hepatitis C reinfection rates are greater in drug users despite successful treatment with direct-acting antiviral therapy.

Understanding how HIV-related stigma can affect patients later in life can lead to new approaches to address cognitive impairment in this population.

Abaloparatide and teriparatide are the only anabolic agents approved by the FDA for women with osteoporosis at high-risk of fragility fractures.

Top news of the day across the health care landscape.

Emerging platforms make it feasible for hepatitis C testing to be conducted in settings that within or outside of health care facilities, such as prisons.

SUBA-itraconazole is indicated for the treatment of blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and aspergillosis, pulmonary and extrapulmonary.

A patient-centric approach is vital to effective specialty pharmacy services.

Study shows that routinely screening inmates for hepatitis C virus at entry may identify a significant number of cases that would have been missed through targeted testing.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, talks about new therapies for hemophilia and exciting advancements on the horizon.

Top news of the day across the health care landscape

Experts argue whether a decline in cognitive function should lead to a change in disease-modifying therapy for multiple sclerosis.

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.

Top news of the day from across the health care landscape.

Top news of the day across the health care landscape.

The specialty drug market saw a 16% growth rate in 2018.

Zimura (avacincaptad pegol) was generally well tolerated when given to patients in combination with ranibizumab (Lucentis), but Ophthotech Corp announced it will focus efforts on other clinical programs.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses specialty areas experiencing innovative developments in therapies.

Top news of the day from across the health care landscape.

Two phase 3 studies evaluating the triple combination regimen met the primary endpoint of improvement in lung function in patients with at least 1 F508del mutation.

Top news of the day from across the health care landscape.

Health care providers managing patients with MS should remain cognizant of the link between unhealthy lifestyle behaviors and depression risks.

Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.

Bodily fluids may serve as vectors for transmission for transmitting hepatitis C virus RNA in patients with a high viral load.